Profitability
Weight: 20%
F
0
- 5yr Avg ROIC -12.4%
- Operating Margin Trend -305.60 pp/yr
TRDA
Entrada Therapeutics, Inc.
AlphaQuality composite grade, weighted for stable earnings power businesses.
⚠ 4 of the last 5 fiscal years showed negative net income — AlphaQuality will not grade above F for persistent unprofitability in a stable earnings power business.
Grade overrides the 16.4 pillar composite — hard gates always win.
Capital Efficiency
Weight: 15%
F
0
- 5yr Avg ROE -19.2%
- 5yr Share-Count CAGR 5.8%
Growth Quality
Weight: 15%
F
20
- Revenue-Growth Years (5) 1/5
Cash Generation
Weight: 15%
F
0
- 5yr FCF Margin -142.3%
- 5yr FCF/NI Conversion -0.68x
Balance Sheet
Weight: 20%
D-
30
- Net Debt / EBITDA 10.00x
- Interest Coverage (EBIT/Int) 30.00x
- Altman Z-Score 0.13
Stability
Weight: 15%
C-
48
- Negative-Revenue Years (5) 1/5
- Piotroski F-Score 2
Guru Flow
Curated superinvestor sentiment — not part of the AlphaQuality grade.2 of 2 gurus held; 1 added; 1 trimmed.
- Holders
- 2 +1
- Avg Δ position
- -59.0%
- New buys
- 0
- Full exits
- 0